Document is current
Any future updates will be listed below
-
Authors
Schwarzenhofer, Daniel C. https://orcid.org/0000-0002-4340-8597
von Oertzen, Tim
Weis, Serge
Sonnberger, Michael
Gruber, Joachim
Tröscher, Anna
Wagner, Helga
Hermann, Philipp
Grubauer, Birgit
Wagner, Judith
-
Funding
Funding for this research was provided by:
Johannes Kepler University Linz
- License Information
-
More Information
Article History
Received: 16 May 2024
Accepted: 2 October 2024
First Online: 11 November 2024
Declarations
:
: D.C. Schwarzenhofer reports an unrestricted grant from Boehringer Ingelheim RCV GmbH & Co. KG. J. Wagner reports personal and congress fees from Boehringer Ingelheim, personal fees from UCB, congress fees from Roche, and congress fees from Janssen-Cilag outside the submitted work. T. von Oertzen received consulting fees or honoraria for lectures from Angelini Pharma, Arvelle, GW Pharma, Jazz Pharma, Liva Nova, and Eisai, as well as travel and meeting support from Angelini Pharma and Jazz Pharma, all outside of this study. S. Weis, M. Sonnberger, J. Gruber, A. Tröscher, H. Wagner, P. Hermann, and B. Grubauer declare that they have no competing interests.
: Ethical approval and consent to participate: the study was approved by the Ethics Committee of the Johannes Kepler University Linz (number: 1180/2020; ), who stated that no informed consent was required. This study was performed in line with the principles of the Declaration of Helsinki. Informed consent was obtained from all individual participants included in the study. All studies mentioned were in accordance with the ethical standards indicated in each case.
